Compare Adaptive Biotechnologies Corp (ADPT) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Adaptive Biotechnologies Corp trades at $20.03 (market cap $3.33B), while First Trust NASDAQ 100 Technology Index Fund trades at $309.37. Which is the better fit depends on your goals.
| ADPT | QTEC | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $335.74 |
52-Week Low | $10.24 | $207.03 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
QTEC trades at $320.77, up 1.84% with neutral technical signals and bullish moving averages. The ETF provides equal-weighted exposure to Nasdaq-100 technology stocks, recently hitting 52-week highs. Support levels cluster around $313-318 while resistance sits at $324-329. Recent news highlights QTEC's role in tech sector exposure amid AI and chip stock momentum.
The ETF's equal-weight approach diversifies tech sector risk, though concentrated tech exposure remains sensitive to sector volatility. Current technical positioning suggests consolidation near pivot points, with institutional interest balanced by valuation concerns in overheated AI segments. Key risks include sector rotation and macroeconomic pressure on growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
